Percentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging.
All patients initially diagnosed with T1, Tis or high grade Ta non-muscle invasive bladder cancer and a qualified encounter in the measurement period.
Equals Initial population
Immunosuppressed patients, includes HIV and immunocompromised state.
Immunosuppressive drug therapy.
Active Tuberculosis.
Mixed histology urothelial cell carcinoma including micropapillary, plasmacytoid, sarcomatoid, adenocarcinoma and squamous disease.
Patients who undergo cystectomy, chemotherapy or radiation within 6 months of Bladder Cancer Staging.
Intravesical Bacillus-Calmette Guerin (BCG) instillation for initial dose or series.
BCG is initiated within 6 months of the bladder cancer staging and during the measurement period.
Not Applicable
Unavailability of BCG
A higher score is the preferred result and indicates better quality
Ta bladder cancer must be high grade Ta only and is supported by the 2016 AUA guidelines and 2018 NCCN guidelines.
The BCG dose can be full or partial and can be from any lot or manufacturer.
This eCQM is a patient-based measure.
Telehealth encounters are not eligible for this measure because the measure requires a clinical action that cannot be conducted via telehealth.
This version of the eCQM uses QDM version 5.5. Please refer to the eCQI resource center (https://ecqi.healthit.gov/qdm) for more information on the QDM.
The Compare function compares two years of the measure specifications found in the header of the measure's HTML. It does not include a comparison of any information in the body of the HTML, e.g., population criteria, Clinical Quality Language, or value sets.
Strikethrough text highlighted in red indicates information changed from the previous version. Text highlighted in green indicates information updated in the new eCQM version.
Percentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging
All patients initially diagnosed with T1, Tis or high grade Ta non-muscle invasive bladder cancer and a qualified encounter in the measurement period
Equals Initial Population
Intravesical Bacillus-Calmette Guerin (BCG) instillation for initial dose or series
BCG is initiated within 6 months of the bladder cancer staging and during the measurement period
This version of the eCQM uses QDM version 5.6. Please refer to the QDM page for more information on the QDM.
Updated the eCQM version number.
Measure Section: eCQM Version Number
Source of Change: Annual Update
Updated copyright.
Measure Section: Copyright
Updated the Rationale to reflect current citations and statistics.
Measure Section: Rationale
Source of Change: Measure Lead
Updated references.
Measure Section: Reference
Corrected spelling of 'immunosupppressed' to 'immunosuppressed' for accuracy.
Measure Section: Denominator Exclusions
Replaced 'overlaps' with 'during' the measurement period for clarity.
Measure Section: Numerator
Replaced 'None' with 'Not Applicable' to conform with Blueprint recommended language.
Measure Section: Numerator Exclusions
Updated punctuation for 'nonmuscle' to 'non-muscle' for consistency.
Measure Section: Multiple Sections
Changed timing in the Bladder Cancer Diagnosis definition from 'starts same day or before' to 'starts before' end of measurement period to reflect measure intent.
Measure Section: Initial Population
Changed timing in the Most Recent Bladder Cancer Staging Procedure definition to 'overlaps day of' bladder cancer prevalence period to correctly meet measure intent.
Updated the names of Clinical Quality Language (CQL) definitions, functions, and/or aliases for clarification and to align with the CQL Style Guide.
Source of Change: Standards Update
Changed timing in the Acute Tuberculosis Diagnosis definition to allow for a resolved diagnosis to no longer be excluded from the measure.
Source of Change: Expert Work Group Review
Updated the version number of the Measure Authoring Tool (MAT) Global Common Functions Library (MATGlobalCommonFunctions-6.2.000). Updated the 'Inpatient Encounter' definition to include a 'day of' timing clarification. Added the following timing functions: Normalize Interval, Has Start, Has End, Latest, Latest Of, Earliest, and Earliest Of. Please see individual measure details for application of specific timing functions.
Changed spelling in 'Has Most Recent Bladder Cancer Tumor Staging isTa HG, Tis, T1' to'Has Most Recent Bladder Cancer Tumor Staging is Ta HG, Tis, T1' for accuracy.
Measure Section: Definition
Changed 'BCG Not Available' definition to 'BCG Not Available Within 6 Months After Bladder Cancer Staging' for clarity.
The VSAC is the source of truth for the value set content, please visit the VSAC for downloads of current value sets.
Value set Immunosuppressive Drugs for Urology Care (2.16.840.1.113762.1.4.1151.32): Deleted 3 RxNorm codes (1654082, 199343, 199967) based on terminology update.
Measure Section: Terminology
Renamed value set Immunocompromised Conditions (2.16.840.1.113883.3.666.5.1940) based on recommended value set naming conventions.
Value set Immunocompromised Conditions (2.16.840.1.113883.3.666.5.1940): Deleted 1 SNOMED CT code (404132005) based on terminology update. Added 3 ICD-10-CM codes (D84.81, D84.821, D84.822) based on new or changed coding guidelines.
Value set Chemotherapy for Advanced Cancer (2.16.840.1.113883.3.7643.3.1048): Deleted 15 RxNorm codes based on terminology update.
Value set HIV (2.16.840.1.113883.3.464.1003.120.12.1003): Added 10 SNOMED codes (838377003, 840498003, 10755671000119100, 15928141000119107, 771119002, 771126002, 771127006, 72631000119101, 79019005, 840442003) based on terminology update.